Proactive Investors - Run By Investors For Investors

Lexaria Bioscience's drug delivery technology offer products that 'taste better, smell better and act more quickly.'

Lexaria Bioscience Corp (CSE: LXX) CEO Chris Bunka says the drug-delivery technology company is poised for growth in the year ahead.

"We help other companies deliver their drugs, or what we call API's, active pharmaceutical ingredients," says Bunka. The company is based in Kelowna, British Columbia.

Bunka says the company helps other companies with drug delivery methods create products that "taste better, smell better and act more quickly." This includes items such as cannaboids, vitamins, NSAIDs, PDE5 inhibitors, nicotine and other molecules.

Lexaria has multiple patents pending in over 40 countries and has patents granted in the USA and in Australia for applications of its DehydraTECHTM delivery technology

Bunka says recent growth at the company has been brisk, however, says more and more jurisdictions are making cannabis edibles legal, which is good news for the company.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
View full LXX profile View Profile

Lexaria Bioscience Corp Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use